You should not expect zero hunger after taking the medication
Foods that never bothered you before might suddenly cause nausea, bloating, or other uncomfortable symptoms
Yin L, Chen X, Lu X, An Y, Zhang T, Yan J
Regulates circadian rhythms and sleep-wake cycles: NAD+ fluctuations drive the molecular clock that controls sleep-wake cycles, with optimal levels supporting restorative sleep
complications and prevention
The most clearly defined groups who may be considered in future include individuals with: Metabolic dysfunction-associated steatotic liver disease (MASLD) particularly those with concurrent obesity, type 2 diabetes, or metabolic syndrome Metabolic dysfunction-associated steatohepatitis (MASH) the progressive inflammatory subtype associated with fibrosis and risk of cirrhosis Obesity with elevated liver enzymes (ALT/AST) where hepatic steatosis has been confirmed on imaging Type 2 diabetes with evidence of hepatic fat accumulation , where current glucose-lowering therapies have not adequately addressed liver disease Patients with significant hepatic fibrosis (stage F2 or above) represent a group with particularly high unmet need, as there are currently no licensed pharmacological treatments specifically approved for MASH in the UK
